SCHEMBL4516097

SCHEMBL4516097

Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)CN(c1cccc(-c3ccccc3)c1)C2=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.50
LCK P06239 2/20 0.50
KDR P35968 2/20 0.50
KIT P10721 2/20 0.50
RIPK2 O43353 2/20 0.47
CSF1R P07333 1/20 0.46
CYP2C9 P11712 2/20 0.46
HSPB1 P04792 1/20 0.46
MAPK11 Q15759 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPK10 P53779 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RAF1 P04049 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4503641 0.94 MAPK14 (0.53) MAPK14LCKKDRKITRIPK2
SCHEMBL4502128 0.90 MAPK14 (0.50) MAPK14LCKKDRRIPK2CSF1R
SCHEMBL4490466 0.87 MAPK14 (0.60) MAPK14LCKKDRRIPK2CSF1R
SCHEMBL4502768 0.85 RIPK2 (0.55) MAPK14LCKKDRKITRIPK2
SCHEMBL4493100 0.85 MAPK14 (0.53) MAPK14LCKKDRRIPK2CSF1R
SCHEMBL4511781 0.84 MAPK14 (0.51) MAPK14LCKKDRKITCSF1R
SCHEMBL4506822 0.83 MAPK14 (0.50) MAPK14LCKKDRKITCSF1R
SCHEMBL4501822 0.81 MAP3K5 (0.49) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4494999 0.81 MAPK14 (0.49) MAPK14LCKKDRKITCSF1R
SCHEMBL4501762 0.81 MAPK14 (0.57) MAPK14LCKKDRCSF1RCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286775-A1 Bicyclic Derivatives as P38 Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-11-19 US claimed
EP-1917241-A2 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS Palau Pharma, S.A. (ES) 2008-05-07 EP claimed
WO-2007000339-A1 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO claimed
US-20090286775-A1 Bicyclic Derivatives as P38 Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
EP-1917241-A2 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS Palau Pharma, S.A. (ES) 2008-05-07 EP disclosed
WO-2007000339-A1 BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286775-A1 Bicyclic Derivatives as P38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPKAPK3 MAPK14 26/4885LCK 173/4885KDR 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.